All News

acne

Acne with JAK Inhibitors

d Jack Cush, MD

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
myositis.jpg

BSR Guideline on Idiopathic Inflammatory Myopathy

d Jack Cush, MD

The British Society of Rheumatology (BSR) has published evidence-based guidelines for idiopathic inflammatory myopathy (IIM) affecting juvenile and adult-onset disease. This rare condition has an estimated prevalence of 5-15 per 100,000 persons.

Read Article
DMARDs,biologics,RA

Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis

d Jack Cush, MD

Analysis of rheumatoid arthritis (RA) data from the British Society for Rheumatology Biologics Register shows that, even after failing three or more biologic or targeted synthetic DMARDs (b/tsDMARDs), patients may continue to benefit from repeated trials of unused b/tsDMARDs. 

Read Article
There is 1.4 million transgender persons in the US. ACP has published a guideline "Care of the Transgender Patient" addressing health disparities, certain cancers, substance abuse, mental health conditions, infections, and chronic diseases. https://t.co/AoBeOzv9YH https://t.co/jKabVELPxH

Links:

Dr. John Cush RheumNow ( View Tweet)
Forbes review on how patients can save on the cost of prescription meds https://t.co/zbFMJdOI0W https://t.co/O2RQSrLwZY

Links:

Dr. John Cush RheumNow ( View Tweet)
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/zrlvJpOhqc https://t.co/rxrEVHuUgm

Links:

Dr. John Cush RheumNow ( View Tweet)
Insurance delays in starting TNF Inhibitors in kids w/ Juvenile Idiopathic Arthritis (91% on DMARDs) - prior authorization required in 98%; 26% of PA requests denied & required appeals, w/ 22% delays > 2+ wks, 25% took 30+ days to start TNFi https://t.co/1TGmM8qOHR https://t.co/EpbrNSbNBl

Links:

Dr. John Cush RheumNow ( View Tweet)
An increasing incidence of RA is driven by increasing # of ACPA-negative RA (but not ACPA-positive RA), partly explained by an ageing population (thus making ACPA-negative RA more prevalent in coming years) https://t.co/AzbYyrOfUG

Links:

Dr. John Cush RheumNow ( View Tweet)

Canadian study of 6012 Pregnancies w/ +COVID-19 PCR test shows Preg pts increased risk of hospitalization (RR 2.65) & ICU adm (RR 5.46) vs gen population and higher risk of preterm birth vs preg women without COVID (RR 1.63) https://t.co/6UAaa0Jf8j https://t.co/aLQbxZArmq

Links:

Dr. John Cush RheumNow ( View Tweet)
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis https://t.co/n1O4g4HpMM https://t.co/ulF1d2gDkG

Links:

Dr. John Cush RheumNow ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/ZGAS6W1Rak

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/jXMAyeCL5t https://t.co/0PB81M3v5h

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA update on Paxlovid - for use pts need to have: - COVID test + - Mild-mod dz @ risk for severe COVID - High risk comorbidity - potential interaction w/ statins, OCPs, HIV meds - Dose adjust (nirmatrelvir) w/ CKD - Dose 3 tabs bid x 5d - Watch LFTs https://t.co/oSqwlKijXq https://t.co/3Yx1C23QSz

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 13 European registries on durability/effect of interleukin-17 (IL-17) inhibition with secukinumab: among 2,017 PsA on secukinumab, retention rates were 86% and 76% at 6 and 12 mos, with 12 mo remission rate of 11% to 16% https://t.co/03sJBSbUy6

Links:

Dr. John Cush RheumNow ( View Tweet)

Did you miss last night's TNR on RA, improving future therapy? We've got you covered. Listen to the playback here. https://t.co/ci6TZOw3VX https://t.co/31gRUaKbQm

Links:

Dr. John Cush RheumNow ( View Tweet)
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/0CkSR2gqaT

Links:

Dr. John Cush RheumNow ( View Tweet)

Korean Health Insurance claims data looked at risk of Aortic Regurgitation, Atrial Fib in Axial Spondyloarthritis - 3:1 comparison of normals found axSpA (n 8877) at signif higher risk for aortic regurgitation (HR 2.55) & AF (1.20) https://t.co/BXLDymQDKZ https://t.co/YtUbwmKpkG

Links:

Dr. John Cush RheumNow ( View Tweet)
RUXCOVID phase 3 RCT ruxolitinib (5mg bid x 14d) + plus standard care in 432 hospitalized COVID-19 showed no benefit over placebo in day 29 primary outcomes (death, respiratory failure (invasive ventilation), or ICU care. https://t.co/eyAit2uOLi https://t.co/R9rA1A4dm5

Links:

Dr. John Cush RheumNow ( View Tweet)
Neural networks of high-res quantitative CT (HR-pQCT) scans allowed for 3D imaging of MCP2 to differentiate normals from #RA & #PsA. 932 of 617 ppts correct AuROC for HC 82%, RA 75%, PsA 68%. UA pts read as 86% RA,11% PsA, & 3% HC https://t.co/wSQgllYgug https://t.co/yA6g55SpeC

Links:

Dr. John Cush RheumNow ( View Tweet)
Thanks so much to all who contributed to April's PsA All the Way campaign on RheumNow. You can find all our PsA content at the link below. Did you learn anything new about PsA from our coverage? https://t.co/Mo7Yf2cu4i https://t.co/LvpuLtF4Mv

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×